Clinical trials: Hepatic Malignancies
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation
CTCs, Pancreatic Cancer
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning…
- Conditions
- CTCs, Pancreatic Cancer, Liver Metastases, Relapse
- Trial name
- NCT07448376
- Testing
- CTC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Breast Cancer, Liver Metastases
Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study
Breast cancer ranks as the top leading malignant tumors among females, and also accounts for the most common cause of tumor related mortality in females worldwide.
- Conditions
- Breast Cancer, Liver Metastases, Surgery
- Trial name
- LIBREAST (NCT04817813)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Miguel Servet
Hepatic Cell Carcinoma
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC
1. To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001) as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders. 2.
- Trial name
- NCT06042842
- Volunteers
- 102 people
- Sponsor
- Assiut University
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatic Carcinoma
Development of a Neuronal Microscope
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%.
- Trial name
- NCT06311396
- Testing
- genetic model
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Hepatic Carcinoma
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245798
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Tang-Du Hospital
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Biliary Cancer
Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.
The purpose of this study is to compare the duration of stent patency of a covered vs. an uncovered biliary self-expandable metal stents (SEMS) placed to relieve biliary obstruction in patients with inoperable extrahepatic…
- Trial name
- SEMS (NCT02930252)
- Testing
- Niti-S Biliary ComVi Stent, Niti-S stent (D type)
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- Azienda USL 1 Imperiese
Breast Cancer Metastatic
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research
Evaluation of patient acceptance and characterization of response behaviour for web-based compared with respective paperbacked patient reported outcomes.
- Trial name
- NCT03132506
- Testing
- patient-reported-outcomes
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen
Hepatic Cancer, Pancreatic Ductal Cancer
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)
Background: Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis).
- Conditions
- Hepatic Cancer, Pancreatic Ductal Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT00923052
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab combination therapy (AtezoBev) is well-known 1st-line therapy for advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05908916
- Testing
- AtezoBev with combined radiotherapy
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)
Although sorafenib is the standard treatment for hepatocellular carcinoma with portal vein invasion, the outcome of these patients remains very poor, with a median survival time of 5.5 to 7.2 months.
- Trial name
- ISBRT01 (NCT04167293)
- Testing
- stereotactic body radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Mian XI
Liver Neoplasms
Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
Remote ischemia precondition could protect the liver from ischemia reperfusion injury in patients undergoing hepatectomy.
- Trial name
- NCT02168608
- Testing
- Remote ischemia precondition, None remote ischemia precondition
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Liver and Kidney Tumours
Thermal Ablation in Larger Liver and Kidney Tumours
This is a clinical research study designed to determine the safety and efficacy of the application of a unique interstitial radio frequency thermal therapy for the treatment of large tumours in the kidney or liver.
- Trial name
- NCT01720706
- Testing
- RFA Loosely wound thermal coil
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Liver Carcinoma, Hepatic Cell Carcinoma
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic…
- Trial name
- NCT06144385
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC
This is a single-arm, open-label study performed at our hospital, patients with progression hepatocellular carcinoma (HCC) met inclusion criteria will be enrolled.
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Lenvatinib
- Trial name
- NCT04791176
- Testing
- concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.